Drug intelligence / Profile preview

TFG-003

Development stage: Preclinical
Lead developer: TreeFrog Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

TFG-003 is an undisclosed, discovery-stage cell therapy program being developed by TreeFrog Therapeutics. The candidate is produced using TreeFrog's proprietary C-Stem™ platform, a closed, bioreactor-based system designed for the high-throughput encapsulation, scalable expansion, and differentiation of human induced pluripotent stem cells (hiPSCs) into ready-to-transplant 3D microtissues.

Beyond the preview

Go deeper on TFG-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TFG-003.

Explore the full profile